Pfizer Inc (PFE)
25.98
+0.60
(+2.34%)
USD |
NYSE |
Apr 19, 16:00
25.92
-0.06
(-0.25%)
After-Hours: 18:46
Pfizer Cash from Financing (Quarterly): 5.442B for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.442B |
| September 30, 2023 | -3.779B |
| June 30, 2023 | 27.17B |
| March 31, 2023 | -2.771B |
| December 31, 2022 | -5.015B |
| September 30, 2022 | -5.761B |
| June 30, 2022 | 2.52B |
| March 31, 2022 | -6.578B |
| December 31, 2021 | -3.351B |
| September 30, 2021 | -1.101B |
| June 30, 2021 | -2.557B |
| March 31, 2021 | -2.807B |
| December 31, 2020 | -13.79B |
| September 30, 2020 | -2.821B |
| June 30, 2020 | 9.159B |
| March 31, 2020 | -2.20B |
| December 31, 2019 | -2.44B |
| September 30, 2019 | 3.273B |
| June 30, 2019 | -851.00M |
| March 31, 2019 | -8.467B |
| December 31, 2018 | -6.407B |
| September 30, 2018 | -1.406B |
| June 30, 2018 | -1.908B |
| March 31, 2018 | -10.72B |
| December 31, 2017 | -3.743B |
| Date | Value |
|---|---|
| September 30, 2017 | -1.711B |
| June 30, 2017 | -2.989B |
| March 31, 2017 | -4.907B |
| December 31, 2016 | -2.313B |
| September 30, 2016 | -1.662B |
| June 30, 2016 | 1.918B |
| March 31, 2016 | -7.171B |
| December 31, 2015 | -1.294B |
| September 30, 2015 | -263.00M |
| June 30, 2015 | -1.874B |
| March 31, 2015 | -6.978B |
| December 31, 2014 | -3.127B |
| September 30, 2014 | -2.887B |
| June 30, 2014 | -2.04B |
| March 31, 2014 | -2.133B |
| December 31, 2013 | -5.744B |
| September 30, 2013 | -5.631B |
| June 30, 2013 | -4.034B |
| March 31, 2013 | 434.00M |
| December 31, 2012 | -6.233B |
| September 30, 2012 | -3.291B |
| June 30, 2012 | -2.968B |
| March 31, 2012 | -3.507B |
| December 31, 2011 | -6.25B |
| September 30, 2011 | -4.035B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-13.79B
Minimum
Dec 2020
27.17B
Maximum
Jun 2023
-434.26M
Average
-2.557B
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | 2.754B |
| Gilead Sciences Inc | -1.099B |
| Johnson & Johnson | -4.655B |
| Viking Therapeutics Inc | 0.188M |
| Moderna Inc | -109.00M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 5.24B |
| Cash from Investing (Quarterly) | -11.00B |
| Free Cash Flow | 4.793B |
| Free Cash Flow Per Share (Quarterly) | 0.7432 |
| Free Cash Flow to Equity (Quarterly) | -3.053B |
| Free Cash Flow to Firm (Quarterly) | 4.260B |
| Free Cash Flow Yield | 3.25% |